790 A phase II study (TACTI-002) of eftilagimod alpha (a soluble LAG-3 protein) with pembrolizumab in PD-L1 unselected patients with metastatic non-small cell lung(NSCLC) or head and neck carcinoma(HNSCC)

Matthew Krebs; Margarita Majem; Enriqueta Felip; Martin Forster; Bernard Doger; Tonya Clay; Enric Carcereny; Julio Peguero; Leora Horn; Pawan Bajaj; Patricia Roxburgh; Chrystelle Brignone; Christian Mueller; Frederic Triebel

doi:10.1136/jitc-2020-SITC2020.0790

790 A phase II study (TACTI-002) of eftilagimod alpha (a soluble LAG-3 protein) with pembrolizumab in PD-L1 unselected patients with metastatic non-small cell lung(NSCLC) or head and neck carcinoma(HNSCC)

Matthew Krebs, Margarita Majem, Enriqueta Felip, Martin Forster, Bernard Doger, Tonya Clay, Enric Carcereny, Julio Peguero, Leora Horn, Pawan Bajaj, Patricia Roxburgh, Chrystelle Brignone, Christian Mueller, Frederic Triebel

Division of Cancer Sciences (L5)

Research output: Contribution to journal › Meeting Abstract › peer-review

Original language	English
Pages (from-to)	A472-A473
Number of pages	2
Journal	Journal for ImmunoTherapy of Cancer
Volume	8
Issue number	Suppl 3
DOIs	https://doi.org/10.1136/jitc-2020-SITC2020.0790
Publication status	Published - 1 Nov 2020

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1136/jitc-2020-SITC2020.0790

Cite this

Krebs, M., Majem, M., Felip, E., Forster, M., Doger, B., Clay, T., Carcereny, E., Peguero, J., Horn, L., Bajaj, P., Roxburgh, P., Brignone, C., Mueller, C., & Triebel, F. (2020). 790 A phase II study (TACTI-002) of eftilagimod alpha (a soluble LAG-3 protein) with pembrolizumab in PD-L1 unselected patients with metastatic non-small cell lung(NSCLC) or head and neck carcinoma(HNSCC). Journal for ImmunoTherapy of Cancer, 8(Suppl 3), A472-A473. https://doi.org/10.1136/jitc-2020-SITC2020.0790

@article{36e0068881834b328aed0615a9a6d7d3,

title = "790 A phase II study (TACTI-002) of eftilagimod alpha (a soluble LAG-3 protein) with pembrolizumab in PD-L1 unselected patients with metastatic non-small cell lung(NSCLC) or head and neck carcinoma(HNSCC)",

author = "Matthew Krebs and Margarita Majem and Enriqueta Felip and Martin Forster and Bernard Doger and Tonya Clay and Enric Carcereny and Julio Peguero and Leora Horn and Pawan Bajaj and Patricia Roxburgh and Chrystelle Brignone and Christian Mueller and Frederic Triebel",

year = "2020",

month = nov,

day = "1",

doi = "10.1136/jitc-2020-SITC2020.0790",

language = "English",

volume = "8",

pages = "A472--A473",

journal = "Journal for ImmunoTherapy of Cancer",

issn = "2051-1426",

publisher = "Springer Nature",

number = "Suppl 3",

}

Krebs, M, Majem, M, Felip, E, Forster, M, Doger, B, Clay, T, Carcereny, E, Peguero, J, Horn, L, Bajaj, P, Roxburgh, P, Brignone, C, Mueller, C & Triebel, F 2020, '790 A phase II study (TACTI-002) of eftilagimod alpha (a soluble LAG-3 protein) with pembrolizumab in PD-L1 unselected patients with metastatic non-small cell lung(NSCLC) or head and neck carcinoma(HNSCC)', Journal for ImmunoTherapy of Cancer, vol. 8, no. Suppl 3, pp. A472-A473. https://doi.org/10.1136/jitc-2020-SITC2020.0790

790 A phase II study (TACTI-002) of eftilagimod alpha (a soluble LAG-3 protein) with pembrolizumab in PD-L1 unselected patients with metastatic non-small cell lung(NSCLC) or head and neck carcinoma(HNSCC). / Krebs, Matthew; Majem, Margarita; Felip, Enriqueta et al.
In: Journal for ImmunoTherapy of Cancer, Vol. 8, No. Suppl 3, 01.11.2020, p. A472-A473.

Research output: Contribution to journal › Meeting Abstract › peer-review

TY - JOUR

T1 - 790 A phase II study (TACTI-002) of eftilagimod alpha (a soluble LAG-3 protein) with pembrolizumab in PD-L1 unselected patients with metastatic non-small cell lung(NSCLC) or head and neck carcinoma(HNSCC)

AU - Krebs, Matthew

AU - Majem, Margarita

AU - Felip, Enriqueta

AU - Forster, Martin

AU - Doger, Bernard

AU - Clay, Tonya

AU - Carcereny, Enric

AU - Peguero, Julio

AU - Horn, Leora

AU - Bajaj, Pawan

AU - Roxburgh, Patricia

AU - Brignone, Chrystelle

AU - Mueller, Christian

AU - Triebel, Frederic

PY - 2020/11/1

Y1 - 2020/11/1

U2 - 10.1136/jitc-2020-SITC2020.0790

DO - 10.1136/jitc-2020-SITC2020.0790

M3 - Meeting Abstract

SN - 2051-1426

VL - 8

SP - A472-A473

JO - Journal for ImmunoTherapy of Cancer

JF - Journal for ImmunoTherapy of Cancer

IS - Suppl 3

ER -

Krebs M, Majem M, Felip E, Forster M, Doger B, Clay T et al. 790 A phase II study (TACTI-002) of eftilagimod alpha (a soluble LAG-3 protein) with pembrolizumab in PD-L1 unselected patients with metastatic non-small cell lung(NSCLC) or head and neck carcinoma(HNSCC). Journal for ImmunoTherapy of Cancer. 2020 Nov 1;8(Suppl 3):A472-A473. doi: 10.1136/jitc-2020-SITC2020.0790